MicroOrganoSphere (MOS) Drug Screen Pilot Trial in Colorectal Cancer
(MODEL-CRC Trial)
Recruiting in Palo Alto (17 mi)
+10 other locations
Age: 18+
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Waitlist Available
Sponsor: Xilis, Inc.
No Placebo Group
Trial Summary
What is the purpose of this trial?
The purpose of the study is to determine the feasibility of generating sufficient MicroOrganoSpheres (MOS) from a biopsy of a subject's adenocarcinoma of the colon and/or rectum that is metastatic to the liver and completing a drug screen against patient-derived MOS using standard of care drugs used in the treatment of colorectal cancer (oxaliplatin, irinotecan, 5-FU/capecitabine (Xeloda), bevacizumab, panitumumab or cetuximab, trifluridine/tipiracil (Lonsurf), regorafenib and pembrolizumab or nivolumab) in ≤ 14 days.
Research Team
SO
Study Official
Principal Investigator
Xilis, Inc.
Eligibility Criteria
Inclusion Criteria
Subject signed a valid, Institutional Review Board (IRB)/Ethics Committee (EC)-approved informed consent form.
Male or female age 18 or older when written informed consent is obtained.
Study candidate is willing and able to comply with all protocol-required procedures and assessments.
See 2 more
Treatment Details
Interventions
- MicroOrganoSphere (MOS) drug screen (Other)
Participant Groups
1Treatment groups
Experimental Treatment
Group I: Metastatic colorectal cancerExperimental Treatment1 Intervention
Patients having a liver biopsy for suspected adenocarcinoma of the colon and/or rectum that is metastatic to the liver.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
The University of Tennessee Medical CenterKnoxville, TN
The University of Texas MD Anderson Cancer CenterHouston, TX
Mayo ClinicRochester, MN
Renown Regional Medical CenterReno, NV
More Trial Locations
Loading ...
Who Is Running the Clinical Trial?
Xilis, Inc.
Lead Sponsor
Trials
1
Patients Recruited
50+